Trial
NCT04520620
Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang
Condition
Sars-CoV2
Intervention
Lovenox 40 MG in 0.4 mL Prefilled Syringe
Why stopped
End of the COVID 19 epidemic in the region and decision to participate in a national study on the same subject (COVI-DOSE).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-20